AroCell Past Earnings Performance

Past criteria checks 0/6

AroCell's earnings have been declining at an average annual rate of -21.8%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 58.6% per year.

Key information

-21.8%

Earnings growth rate

14.2%

EPS growth rate

Life Sciences Industry Growth31.8%
Revenue growth rate58.6%
Return on equity-38.8%
Net Margin-98.0%
Next Earnings Update19 Feb 2025

Recent past performance updates

Recent updates

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

Apr 20
Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Feb 27
Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Nov 07
At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

Aug 10
We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

Apr 18
AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Jan 03
We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How AroCell makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:AROC Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2452-513523
30 Jun 2448-543425
31 Mar 2445-563425
31 Dec 2343-593325
30 Sep 2346-593526
30 Jun 2346-573525
31 Mar 2340-573525
31 Dec 2237-593624
30 Sep 2230-623624
30 Jun 2226-693725
31 Mar 2220-593123
31 Dec 2112-502620
30 Sep 216-361816
30 Jun 210-251213
31 Mar 210-251213
31 Dec 200-241113
30 Sep 200-241212
30 Jun 200-221211
31 Mar 200-211110
31 Dec 190-211110
30 Sep 190-201010
30 Jun 190-211110
31 Mar 191-221110
31 Dec 181-211010
30 Sep 181-211110
30 Jun 181-19109
31 Mar 180-1798
31 Dec 171-17108
30 Sep 170-1395
30 Jun 170-1294
31 Mar 170-11101
31 Dec 160-972
30 Sep 161-982
30 Jun 160-881
31 Mar 160-881
31 Dec 150-780
30 Sep 150-990
30 Jun 150-880
31 Mar 150-880
31 Dec 140-660
30 Sep 140-550
30 Jun 140-540
31 Mar 140-440

Quality Earnings: AROC is currently unprofitable.

Growing Profit Margin: AROC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AROC is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare AROC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AROC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (36%).


Return on Equity

High ROE: AROC has a negative Return on Equity (-38.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AroCell AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar BergmanRedeye